全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...
Genes  2013 

Roles of EphA2 in Development and Disease

DOI: 10.3390/genes4030334

Keywords: EphA2, ephrin, development, cataract, kidney, bone, ear, mammary gland

Full-Text   Cite this paper   Add to My Lib

Abstract:

The Eph family of receptor tyrosine kinases (RTKs) has been implicated in the regulation of many aspects of mammalian development. Recent analyses have revealed that the EphA2 receptor is a key modulator for a wide variety of cellular functions. This review focuses on the roles of EphA2 in both development and disease.

 References

[1]  Van der Geer, P.; Hunter, T.; Lindberg, R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell. Biol. 1994, 10, 251–337, doi:10.1146/annurev.cb.10.110194.001343.
[2]  Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141, 1117–1134, doi:10.1016/j.cell.2010.06.011.
[3]  Fox, G.M.; Holst, P.L.; Chute, H.T.; Lindberg, R.A.; Janssen, A.M.; Basu, R.; Welcher, A.A. cDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases. Oncogene 1995, 10, 897–905.
[4]  Gurniak, C.B.; Berg, L.J. A new member of the Eph family of receptors that lacks protein tyrosine kinase activity. Oncogene 1996, 13, 777–786.
[5]  Pandey, A.; Lindberg, R.A.; Dixit, V.M. Cell signalling. Receptor orphans find a family. Curr. Biol. 1995, 5, 986–989, doi:10.1016/S0960-9822(95)00195-3.
[6]  Zhou, R. The Eph family receptors and ligands. Pharmacol. Ther. 1998, 77, 151–181, doi:10.1016/S0163-7258(97)00112-5.
[7]  Holder, N.; Klein, R. Eph receptors and ephrins: Effectors of morphogenesis. Development 1999, 126, 2033–2044.
[8]  Flenniken, A.M.; Gale, N.W.; Yancopoulos, G.D.; Wilkinson, D.G. Distinct and overlapping expression patterns of ligands for Eph-related receptor tyrosine kinases during mouse embryogenesis. Dev. Biol. 1996, 179, 382–401, doi:10.1006/dbio.1996.0269.
[9]  Rohani, N.; Canty, L.; Luu, O.; Fagotto, F.; Winklbauer, R. EphrinB/EphB signaling controls embryonic germ layer separation by contact-induced cell detachment. PLoS Biol. 2011, 9, e1000597.
[10]  Mellitzer, G.; Xu, Q.; Wilkinson, D.G. Eph receptors and ephrins restrict cell intermingling and communication. Nature 1999, 400, 77–81, doi:10.1038/21907.
[11]  Xu, Q.; Mellitzer, G.; Robinson, V.; Wilkinson, D.G. In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature 1999, 399, 267–271.
[12]  Robinson, V.; Smith, A.; Flenniken, A.M.; Wilkinson, D.G. Roles of Eph receptors and ephrins in neural crest pathfinding. Cell Tissue Res. 1997, 290, 265–274, doi:10.1007/s004410050931.
[13]  Smith, A.; Robinson, V.; Patel, K.; Wilkinson, D.G. The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells. Curr. Biol. 1997, 7, 561–570, doi:10.1016/S0960-9822(06)00255-7.
[14]  Flanagan, J.G.; Vanderhaeghen, P. The ephrins and Eph receptors in neural development. Annu. Rev. Neurosci. 1998, 21, 309–345, doi:10.1146/annurev.neuro.21.1.309.
[15]  Orioli, D.; Klein, R. The Eph receptor family: Axonal guidance by contact repulsion. Trends Genet. 1997, 13, 354–359, doi:10.1016/S0168-9525(97)01220-1.
[16]  Egea, J.; Klein, R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell. Biol. 2007, 17, 230–238, doi:10.1016/j.tcb.2007.03.004.
[17]  Wilkinson, D.G. Multiple roles of EPH receptors and ephrins in neural development. Nat. Rev. Neurosci. 2001, 2, 155–164, doi:10.1038/35058515.
[18]  Palmer, A.; Klein, R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev. 2003, 17, 1429–1450, doi:10.1101/gad.1093703.
[19]  Edwards, C.M.; Mundy, G.R. Eph receptors and ephrin signaling pathways: A role in bone homeostasis. Int. J. Med. Sci. 2008, 5, 263–272, doi:10.7150/ijms.5.263.
[20]  Matsuo, K.; Otaki, N. Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases. Cell Adhes. Migr. 2012, 6, 148–156, doi:10.4161/cam.20888.
[21]  Zhao, C.; Irie, N.; Takada, Y.; Shimoda, K.; Miyamoto, T.; Nishiwaki, T.; Suda, T.; Matsuo, K. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006, 4, 111–121, doi:10.1016/j.cmet.2006.05.012.
[22]  Irie, N.; Takada, Y.; Watanabe, Y.; Matsuzaki, Y.; Naruse, C.; Asano, M.; Iwakura, Y.; Suda, T.; Matsuo, K. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J. Biol. Chem. 2009, 284, 14637–14644, doi:10.1074/jbc.M807598200.
[23]  Gale, N.W.; Yancopoulos, G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 1999, 13, 1055–1066, doi:10.1101/gad.13.9.1055.
[24]  Pandey, A.; Shao, H.; Marks, R.M.; Polverini, P.J.; Dixit, V.M. Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis. Science 1995, 268, 567–569.
[25]  Wang, H.U.; Chen, Z.F.; Anderson, D.J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93, 741–753, doi:10.1016/S0092-8674(00)81436-1.
[26]  Adams, R.H.; Wilkinson, G.A.; Weiss, C.; Diella, F.; Gale, N.W.; Deutsch, U.; Risau, W.; Klein, R. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999, 13, 295–306, doi:10.1101/gad.13.3.295.
[27]  Adams, R.H.; Diella, F.; Hennig, S.; Helmbacher, F.; Deutsch, U.; Klein, R. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell 2001, 104, 57–69, doi:10.1016/S0092-8674(01)00191-X.
[28]  Brantley-Sieders, D.M.; Chen, J. Eph receptor tyrosine kinases in angiogenesis: From development to disease. Angiogenesis 2004, 7, 17–28, doi:10.1023/B:AGEN.0000037340.33788.87.
[29]  Shen, J.; Xie, B.; Hatara, C.M.; Hackett, S.F.; Campochiaro, P.A. Vegf or EphA2 antisense polyamide-nucleic acids; vascular localization and suppression of retinal neovascularization. Mol. Ther. 2007, 15, 1924–1930, doi:10.1038/sj.mt.6300276.
[30]  Coulthard, M.G.; Duffy, S.; Down, M.; Evans, B.; Power, M.; Smith, F.; Stylianou, C.; Kleikamp, S.; Oates, A.; Lackmann, M.; et al. The role of the Eph-ephrin signalling system in the regulation of developmental patterning. Int. J. Dev. Biol. 2002, 46, 375–384.
[31]  Pasquale, E.B. Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat. Rev. Cancer 2010, 10, 165–180, doi:10.1038/nrc2806.
[32]  Hafner, C.; Schmitz, G.; Meyer, S.; Bataille, F.; Hau, P.; Langmann, T.; Dietmaier, W.; Landthaler, M.; Vogt, T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 2004, 50, 490–499, doi:10.1373/clinchem.2003.026849.
[33]  Andres, A.C.; Zuercher, G.; Djonov, V.; Flueck, M.; Ziemiecki, A. Protein tyrosine kinase expression during the estrous cycle and carcinogenesis of the mammary gland. Int. J. Cancer 1995, 63, 288–296, doi:10.1002/ijc.2910630224.
[34]  Andres, A.C.; Reid, H.H.; Zurcher, G.; Blaschke, R.J.; Albrecht, D.; Ziemiecki, A. Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis. Oncogene 1994, 9, 1461–1467.
[35]  Jun, G.; Guo, H.; Klein, B.E.; Klein, R.; Wang, J.J.; Mitchell, P.; Miao, H.; Lee, K.E.; Joshi, T.; Buck, M.; et al. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet. 2009, 5, e1000584, doi:10.1371/journal.pgen.1000584.
[36]  Shiels, A.; Bennett, T.M.; Knopf, H.L.; Maraini, G.; Li, A.; Jiao, X.; Hejtmancik, J.F. The EPHA2 gene is associated with cataracts linked to chromosome 1p. Mol. Vis. 2008, 14, 2042–2055.
[37]  Kaul, H.; Riazuddin, S.A.; Shahid, M.; Kousar, S.; Butt, N.H.; Zafar, A.U.; Khan, S.N.; Husnain, T.; Akram, J.; Hejtmancik, J.F.; et al. Autosomal recessive congenital cataract linked to EPHA2 in a consanguineous Pakistani family. Mol. Vis. 2010, 16, 511–517.
[38]  Zhang, T.; Hua, R.; Xiao, W.; Burdon, K.P.; Bhattacharya, S.S.; Craig, J.E.; Shang, D.; Zhao, X.; Mackey, D.A.; Moore, A.T.; et al. Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum. Mutat. 2009, 30, E603–E611, doi:10.1002/humu.20995.
[39]  Tan, W.; Hou, S.; Jiang, Z.; Hu, Z.; Yang, P.; Ye, J. Association of EPHA2 polymorphisms and age-related cortical cataract in a Han Chinese population. Mol. Vis. 2011, 17, 1553–1558.
[40]  Sundaresan, P.; Ravindran, R.D.; Vashist, P.; Shanker, A.; Nitsch, D.; Talwar, B.; Maraini, G.; Camparini, M.; Nonyane, B.A.; Smeeth, L.; et al. EPHA2 polymorphisms and age-related cataract in India. PLoS One 2012, 7, e33001, doi:10.1371/journal.pone.0033001.
[41]  Shentu, X.C.; Zhao, S.J.; Zhang, L.; Miao, Q. A novel p.R890C mutation in EPHA2 gene associated with progressive childhood posterior cataract in a Chinese family. Int. J. Ophthalmol. 2013, 6, 34–38.
[42]  Miao, H.; Nickel, C.H.; Cantley, L.G.; Bruggeman, L.A.; Bennardo, L.N.; Wang, B. EphA kinase activation regulates HGF-induced epithelial branching morphogenesis. J. Cell. Biol. 2003, 162, 1281–1292, doi:10.1083/jcb.200304018.
[43]  Xu, H.; Tian, W.; Lindsley, J.N.; Oyama, T.T.; Capasso, J.M.; Rivard, C.J.; Cohen, H.T.; Bagnasco, S.M.; Anderson, S.; Cohen, D.M. EphA2: Expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo. Am. J. Physiol. Renal Physiol. 2005, 288, F855–F866.
[44]  Kouros-Mehr, H.; Werb, Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev. Dyn. 2006, 235, 3404–3412, doi:10.1002/dvdy.20978.
[45]  Zelinski, D.P.; Zantek, N.D.; Stewart, J.C.; Irizarry, A.R.; Kinch, M.S. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001, 61, 2301–2306.
[46]  Vaught, D.; Chen, J.; Brantley-Sieders, D.M. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase. Mol. Biol. Cell 2009, 20, 2572–2581, doi:10.1091/mbc.E08-04-0378.
[47]  Park, J.E.; Son, A.I.; Hua, R.; Wang, L.; Zhang, X.; Zhou, R. Human cataract mutations in EPHA2 SAM domain alter receptor stability and function. PLoS One 2012, 7, e36564.
[48]  Saeger, B.M.; Suhm, M.; Neubuser, A. Ephrin/ephrin receptor expression during early stages of mouse inner ear development. Dev. Dyn. 2011, 240, 1578–1585, doi:10.1002/dvdy.22632.
[49]  Lin, S.; Wang, B.; Getsios, S. Eph/ephrin signaling in epidermal differentiation and disease. Semin. Cell Dev. Biol. 2012, 23, 92–101, doi:10.1016/j.semcdb.2011.10.017.
[50]  Arvanitis, D.; Davy, A. Eph/ephrin signaling: Networks. Genes Dev. 2008, 22, 416–429, doi:10.1101/gad.1630408.
[51]  Vaught, D.; Brantley-Sieders, D.M.; Chen, J. Eph receptors in breast cancer: Roles in tumor promotion and tumor suppression. Breast Cancer Res. 2008, 10, 217.
[52]  Chen, J. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv. Cancer Res. 2012, 114, 1–20.
[53]  Janes, P.W.; Nievergall, E.; Lackmann, M. Concepts and consequences of Eph receptor clustering. Semin. Cell Dev. Biol. 2012, 23, 43–50, doi:10.1016/j.semcdb.2012.01.001.
[54]  Funk, S.D.; Orr, A.W. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacol. Res. 2013, 67, 42–52, doi:10.1016/j.phrs.2012.10.008.
[55]  Chen, J.; Zhuang, G.; Frieden, L.; Debinski, W. Eph receptors and Ephrins in cancer: Common themes and controversies. Cancer Res. 2008, 68, 10031–10033, doi:10.1158/0008-5472.CAN-08-3010.
[56]  Wykosky, J.; Debinski, W. The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol. Cancer Res. 2008, 6, 1795–1806, doi:10.1158/1541-7786.MCR-08-0244.
[57]  Hirai, H.; Maru, Y.; Hagiwara, K.; Nishida, J.; Takaku, F. A novel putative tyrosine kinase receptor encoded by the eph gene. Science 1987, 238, 1717–1720.
[58]  Eph Nomenclature Committee. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Cell 1997, 90, 403–404, doi:10.1016/S0092-8674(00)80500-0.
[59]  Bartley, T.D.; Hunt, R.W.; Welcher, A.A.; Boyle, W.J.; Parker, V.P.; Lindberg, R.A.; Lu, H.S.; Colombero, A.M.; Elliott, R.L.; Guthrie, B.A.; et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature 1994, 368, 558–560, doi:10.1038/368558a0.
[60]  Pasquale, E.B. The Eph family of receptors. Curr. Opin. Cell. Biol. 1997, 9, 608–615, doi:10.1016/S0955-0674(97)80113-5.
[61]  Gale, N.W.; Holland, S.J.; Valenzuela, D.M.; Flenniken, A.; Pan, L.; Ryan, T.E.; Henkemeyer, M.; Strebhardt, K.; Hirai, H.; Wilkinson, D.G.; et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996, 17, 9–19, doi:10.1016/S0896-6273(00)80276-7.
[62]  Qin, H.; Noberini, R.; Huan, X.; Shi, J.; Pasquale, E.B.; Song, J. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J. Biol. Chem. 2010, 285, 644–654.
[63]  Takemoto, M.; Fukuda, T.; Sonoda, R.; Murakami, F.; Tanaka, H.; Yamamoto, N. Ephrin-B3-EphA4 interactions regulate the growth of specific thalamocortical axon populations in vitro. Eur. J. Neurosci. 2002, 16, 1168–1172.
[64]  Himanen, J.P.; Chumley, M.J.; Lackmann, M.; Li, C.; Barton, W.A.; Jeffrey, P.D.; Vearing, C.; Geleick, D.; Feldheim, D.A.; Boyd, A.W.; et al. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 2004, 7, 501–509, doi:10.1038/nn1237.
[65]  Himanen, J.P.; Nikolov, D.B. Eph signaling: A structural view. Trends Neurosci. 2003, 26, 46–51, doi:10.1016/S0166-2236(02)00005-X.
[66]  Qiao, F.; Bowie, J.U. The many faces of SAM. Sci. STKE 2005, 2005, re7, doi:10.1126/stke.2862005re7.
[67]  Hui, S.; Xing, X.; Bader, G.D. Predicting PDZ domain mediated protein interactions from structure. BMC Bioinformatics 2013, 14, 27, doi:10.1186/1471-2105-14-27.
[68]  Hock, B.; Bohme, B.; Karn, T.; Yamamoto, T.; Kaibuchi, K.; Holtrich, U.; Holland, S.; Pawson, T.; Rubsamen-Waigmann, H.; Strebhardt, K. PDZ-domain-mediated interaction of the Eph-related receptor tyrosine kinase EphB3 and the ras-binding protein AF6 depends on the kinase activity of the receptor. Proc. Natl. Acad. Sci. USA 1998, 95, 9779–9784, doi:10.1073/pnas.95.17.9779.
[69]  Smalla, M.; Schmieder, P.; Kelly, M.; Ter Laak, A.; Krause, G.; Ball, L.; Wahl, M.; Bork, P.; Oschkinat, H. Solution structure of the receptor tyrosine kinase EphB2 SAM domain and identification of two distinct homotypic interaction sites. Protein Sci. 1999, 8, 1954–1961, doi:10.1110/ps.8.10.1954.
[70]  Thanos, C.D.; Goodwill, K.E.; Bowie, J.U. Oligomeric structure of the human EphB2 receptor SAM domain. Science 1999, 283, 833–836, doi:10.1126/science.283.5403.833.
[71]  Slaughter, B.D.; Huff, J.M.; Wiegraebe, W.; Schwartz, J.W.; Li, R. SAM domain-based protein oligomerization observed by live-cell fluorescence fluctuation spectroscopy. PLoS One 2008, 3, e1931, doi:10.1371/journal.pone.0001931.
[72]  Poliakov, A.; Cotrina, M.; Wilkinson, D.G. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell. 2004, 7, 465–480, doi:10.1016/j.devcel.2004.09.006.
[73]  Pasquale, E.B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 2005, 6, 462–475, doi:10.1038/nrm1662.
[74]  Kullander, K.; Klein, R. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell. Biol. 2002, 3, 475–486, doi:10.1038/nrm856.
[75]  Himanen, J.P.; Yermekbayeva, L.; Janes, P.W.; Walker, J.R.; Xu, K.; Atapattu, L.; Rajashankar, K.R.; Mensinga, A.; Lackmann, M.; Nikolov, D.B.; et al. Architecture of Eph receptor clusters. Proc. Natl. Acad. Sci. USA 2010, 107, 10860–10865, doi:10.1073/pnas.1004148107.
[76]  Noren, N.K.; Pasquale, E.B. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cell. Signal. 2004, 16, 655–666, doi:10.1016/j.cellsig.2003.10.006.
[77]  Klein, R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat. Neurosci. 2009, 12, 15–20, doi:10.1038/nn.2231.
[78]  Murai, K.K.; Pasquale, E.B. 'Eph'ective signaling: Forward, reverse and crosstalk. J. Cell. Sci. 2003, 116, 2823–2832, doi:10.1242/jcs.00625.
[79]  Lim, Y.S.; McLaughlin, T.; Sung, T.C.; Santiago, A.; Lee, K.F.; O’Leary, D.D. p75(NTR) mediates ephrin-A reverse signaling required for axon repulsion and mapping. Neuron 2008, 59, 746–758, doi:10.1016/j.neuron.2008.07.032.
[80]  Yamazaki, T.; Masuda, J.; Omori, T.; Usui, R.; Akiyama, H.; Maru, Y. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J. Cell. Sci. 2009, 122, 243–255, doi:10.1242/jcs.036467.
[81]  Lee, H.S.; Daar, I.O. EphrinB reverse signaling in cell-cell adhesion: Is it just par for the course? Cell Adhes. Migr. 2009, 3, 250–255, doi:10.4161/cam.3.3.8211.
[82]  Carter, N.; Nakamoto, T.; Hirai, H.; Hunter, T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat. Cell Biol. 2002, 4, 565–573.
[83]  Hattori, M.; Osterfield, M.; Flanagan, J.G. Regulated cleavage of a contact-mediated axon repellent. Science 2000, 289, 1360–1365, doi:10.1126/science.289.5483.1360.
[84]  Sharfe, N.; Freywald, A.; Toro, A.; Roifman, C.M. Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells. J. Immunol. 2003, 170, 6024–6032.
[85]  Walker-Daniels, J.; Riese, D.J., 2nd; Kinch, M.S. c-Cbl-dependent EphA2 protein degradation is induced by ligand binding. Mol. Cancer Res. 2002, 1, 79–87.
[86]  Wang, Y.; Ota, S.; Kataoka, H.; Kanamori, M.; Li, Z.; Band, H.; Tanaka, M.; Sugimura, H. Negative regulation of EphA2 receptor by Cbl. Biochem. Biophys. Res. Commun. 2002, 296, 214–220, doi:10.1016/S0006-291X(02)00806-9.
[87]  Marmor, M.D.; Yarden, Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 2004, 23, 2057–2070, doi:10.1038/sj.onc.1207390.
[88]  Palmer, A.; Zimmer, M.; Erdmann, K.S.; Eulenburg, V.; Porthin, A.; Heumann, R.; Deutsch, U.; Klein, R. EphrinB phosphorylation and reverse signaling: Regulation by Src kinases and PTP-BL phosphatase. Mol. Cell 2002, 9, 725–737, doi:10.1016/S1097-2765(02)00488-4.
[89]  Baldwin, C.; Chen, Z.W.; Bedirian, A.; Yokota, N.; Nasr, S.H.; Rabb, H.; Lemay, S. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: Role of Src kinases. Am. J. Physiol. Renal Physiol. 2006, 291, F960–F971, doi:10.1152/ajprenal.00020.2006.
[90]  Dodelet, V.C.; Pazzagli, C.; Zisch, A.H.; Hauser, C.A.; Pasquale, E.B. A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1. J. Biol. Chem. 1999, 274, 31941–31946, doi:10.1074/jbc.274.45.31941 .
[91]  Marston, D.J.; Dickinson, S.; Nobes, C.D. Rac-dependent trans-endocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat. Cell Biol. 2003, 5, 879–888, doi:10.1038/ncb1044.
[92]  Lu, Q.; Sun, E.E.; Klein, R.S.; Flanagan, J.G. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoattraction. Cell 2001, 105, 69–79, doi:10.1016/S0092-8674(01)00297-5.
[93]  Feng, Y.X.; Zhao, J.S.; Li, J.J.; Wang, T.; Cheng, S.Q.; Yuan, Y.; Wang, F.; Wang, X.F.; Xie, D. Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway 120. Hepatology 2010, 51, 535–544, doi:10.1002/hep.23313.
[94]  Zhuang, G.; Hunter, S.; Hwang, Y.; Chen, J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J. Biol. Chem. 2007, 282, 2683–2694, doi:10.1074/jbc.M608509200.
[95]  Fang, W.B.; Ireton, R.C.; Zhuang, G.; Takahashi, T.; Reynolds, A.; Chen, J. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J. Cell Sci. 2008, 121, 358–368, doi:10.1242/jcs.017145.
[96]  Margolis, S.S.; Salogiannis, J.; Lipton, D.M.; Mandel-Brehm, C.; Wills, Z.P.; Mardinly, A.R.; Hu, L.; Greer, P.L.; Bikoff, J.B.; Ho, H.Y.; et al. EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 2010, 143, 442–455, doi:10.1016/j.cell.2010.09.038.
[97]  Brantley-Sieders, D.M.; Zhuang, G.; Hicks, D.; Fang, W.B.; Hwang, Y.; Cates, J.M.; Coffman, K.; Jackson, D.; Bruckheimer, E.; Muraoka-Cook, R.S.; et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 2008, 118, 64–78, doi:10.1172/JCI33154.
[98]  Cowan, C.A.; Henkemeyer, M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature 2001, 413, 174–179, doi:10.1038/35093123.
[99]  Bruckner, K.; Pablo Labrador, J.; Scheiffele, P.; Herb, A.; Seeburg, P.H.; Klein, R. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron 1999, 22, 511–524, doi:10.1016/S0896-6273(00)80706-0.
[100]  Ellis, C.; Kasmi, F.; Ganju, P.; Walls, E.; Panayotou, G.; Reith, A.D. A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn. Oncogene 1996, 12, 1727–1736.
[101]  Kalo, M.S.; Pasquale, E.B. Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry 1999, 38, 14396–14408, doi:10.1021/bi991628t.
[102]  Stein, E.; Huynh-Do, U.; Lane, A.A.; Cerretti, D.P.; Daniel, T.O. Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J. Biol. Chem. 1998, 273, 1303–1308.
[103]  Han, D.C.; Shen, T.L.; Miao, H.; Wang, B.; Guan, J.L. EphB1 associates with Grb7 and regulates cell migration. J. Biol. Chem. 2002, 277, 45655–45661.
[104]  Holland, S.J.; Gale, N.W.; Gish, G.D.; Roth, R.A.; Songyang, Z.; Cantley, L.C.; Henkemeyer, M.; Yancopoulos, G.D.; Pawson, T. Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J. 1997, 16, 3877–3888, doi:10.1093/emboj/16.13.3877.
[105]  Hu, Q.; Milfay, D.; Williams, L.T. Binding of NCK to SOS and activation of ras-dependent gene expression. Mol. Cell. Biol. 1995, 15, 1169–1174.
[106]  Han, D.C.; Shen, T.L.; Guan, J.L. The Grb7 family proteins: Structure, interactions with other signaling molecules and potential cellular functions. Oncogene 2001, 20, 6315–6321, doi:10.1038/sj.onc.1204775.
[107]  Cheng, N.; Brantley, D.M.; Chen, J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002, 13, 75–85, doi:10.1016/S1359-6101(01)00031-4.
[108]  Singh, A.; Winterbottom, E.; Daar, I.O. Eph/ephrin signaling in cell-cell and cell-substrate adhesion. Front. Biosci. 2012, 17, 473–497, doi:10.2741/3939.
[109]  Lindberg, R.A.; Hunter, T. cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol. Cell Biol. 1990, 10, 6316–6324.
[110]  Sulman, E.P.; Tang, X.X.; Allen, C.; Biegel, J.A.; Pleasure, D.E.; Brodeur, G.M.; Ikegaki, N. ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 1997, 40, 371–374, doi:10.1006/geno.1996.4569.
[111]  Ruiz, J.C.; Robertson, E.J. The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development. Mech. Dev. 1994, 46, 87–100, doi:10.1016/0925-4773(94)90078-7.
[112]  Cooper, M.A.; Son, A.I.; Komlos, D.; Sun, Y.; Kleiman, N.J.; Zhou, R. Loss of ephrin-A5 function disrupts lens fiber cell packing and leads to cataract. Proc. Natl. Acad. Sci. USA 2008, 105, 16620–16625.
[113]  Noberini, R.; Koolpe, M.; Peddibhotla, S.; Dahl, R.; Su, Y.; Cosford, N.D.; Roth, G.P.; Pasquale, E.B. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J. Biol. Chem. 2008, 283, 29461–29472, doi:10.1074/jbc.M804103200.
[114]  Walker-Daniels, J.; Hess, A.R.; Hendrix, M.J.; Kinch, M.S. Differential regulation of EphA2 in normal and malignant cells. Am. J. Pathol. 2003, 162, 1037–1042, doi:10.1016/S0002-9440(10)63899-0.
[115]  Davis, S.; Gale, N.W.; Aldrich, T.H.; Maisonpierre, P.C.; Lhotak, V.; Pawson, T.; Goldfarb, M.; Yancopoulos, G.D. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994, 266, 816–819.
[116]  Pawson, T.; Nash, P. Protein-protein interactions define specificity in signal transduction. Genes Dev. 2000, 14, 1027–1047.
[117]  Foster, A.; Resnikoff, S. The impact of Vision 2020 on global blindness. Eye (Lond.) 2005, 19, 1133–1135, doi:10.1038/sj.eye.6701973.
[118]  Rahi, J.S.; Dezateux, C. Measuring and interpreting the incidence of congenital ocular anomalies: Lessons from a national study of congenital cataract in the UK. Invest. Ophthalmol. Vis. Sci. 2001, 42, 1444–1448.
[119]  Shiels, A.; Mackay, D.; Ionides, A.; Berry, V.; Moore, A.; Bhattacharya, S. A missense mutation in the human connexin50 gene (GJA8) underlies autosomal dominant “zonular pulverulent” cataract, on chromosome 1q. Am. J. Hum. Genet. 1998, 62, 526–532, doi:10.1086/301762.
[120]  Mackay, D.; Ionides, A.; Kibar, Z.; Rouleau, G.; Berry, V.; Moore, A.; Shiels, A.; Bhattacharya, S. Connexin46 mutations in autosomal dominant congenital cataract. Am. J. Hum. Genet. 1999, 64, 1357–1364, doi:10.1086/302383.
[121]  Litt, M.; Kramer, P.; LaMorticella, D.M.; Murphey, W.; Lovrien, E.W.; Weleber, R.G. Autosomal dominant congenital cataract associated with a missense mutation in the human alpha crystallin gene CRYAA. Hum. Mol. Genet. 1998, 7, 471–474, doi:10.1093/hmg/7.3.471.
[122]  Berry, V.; Francis, P.; Reddy, M.A.; Collyer, D.; Vithana, E.; MacKay, I.; Dawson, G.; Carey, A.H.; Moore, A.; Bhattacharya, S.S.; et al. Alpha-B crystallin gene (CRYAB) mutation causes dominant congenital posterior polar cataract in humans. Am. J. Hum. Genet. 2001, 69, 1141–1145, doi:10.1086/324158.
[123]  Mackay, D.S.; Boskovska, O.B.; Knopf, H.L.; Lampi, K.J.; Shiels, A. A nonsense mutation in CRYBB1 associated with autosomal dominant cataract linked to human chromosome 22q. Am. J. Hum. Genet. 2002, 71, 1216–1221, doi:10.1086/344212.
[124]  Litt, M.; Carrero-Valenzuela, R.; LaMorticella, D.M.; Schultz, D.W.; Mitchell, T.N.; Kramer, P.; Maumenee, I.H. Autosomal dominant cerulean cataract is associated with a chain termination mutation in the human beta-crystallin gene CRYBB2. Hum. Mol. Genet. 1997, 6, 665–668, doi:10.1093/hmg/6.5.665.
[125]  Riazuddin, S.A.; Yasmeen, A.; Yao, W.; Sergeev, Y.V.; Zhang, Q.; Zulfiqar, F.; Riaz, A.; Riazuddin, S.; Hejtmancik, J.F. Mutations in betaB3-crystallin associated with autosomal recessive cataract in two Pakistani families. Invest. Ophthalmol. Vis. Sci. 2005, 46, 2100–2106, doi:10.1167/iovs.04-1481.
[126]  Kannabiran, C.; Rogan, P.K.; Olmos, L.; Basti, S.; Rao, G.N.; Kaiser-Kupfer, M.; Hejtmancik, J.F. Autosomal dominant zonular cataract with sutural opacities is associated with a splice mutation in the betaA3/A1-crystallin gene. Mol. Vis. 1998, 4, 21.
[127]  Billingsley, G.; Santhiya, S.T.; Paterson, A.D.; Ogata, K.; Wodak, S.; Hosseini, S.M.; Manisastry, S.M.; Vijayalakshmi, P.; Gopinath, P.M.; Graw, J.; Heon, E. CRYBA4, a novel human cataract gene, is also involved in microphthalmia. Am. J. Hum. Genet. 2006, 79, 702–709, doi:10.1086/507712.
[128]  Sun, H.; Ma, Z.; Li, Y.; Liu, B.; Li, Z.; Ding, X.; Gao, Y.; Ma, W.; Tang, X.; Li, X.; et al. Gamma-S crystallin gene (CRYGS) mutation causes dominant progressive cortical cataract in humans. J. Med. Genet. 2005, 42, 706–710, doi:10.1136/jmg.2004.028274.
[129]  Heon, E.; Priston, M.; Schorderet, D.F.; Billingsley, G.D.; Girard, P.O.; Lubsen, N.; Munier, F.L. The gamma-crystallins and human cataracts: A puzzle made clearer. Am. J. Hum. Genet. 1999, 65, 1261–1267, doi:10.1086/302619.
[130]  Muller, M.; Bhattacharya, S.S.; Moore, T.; Prescott, Q.; Wedig, T.; Herrmann, H.; Magin, T.M. Dominant cataract formation in association with a vimentin assembly disrupting mutation. Hum. Mol. Genet. 2009, 18, 1052–1057, doi:10.1093/hmg/ddn440.
[131]  Shi, Y.; de Maria, A.; Bennett, T.; Shiels, A.; Bassnett, S. A role for epha2 in cell migration and refractive organization of the ocular lens. Invest. Ophthalmol. Vis. Sci. 2012, 53, 551–559, doi:10.1167/iovs.11-8568.
[132]  Cheng, C.; Gong, X. Diverse roles of Eph/ephrin signaling in the mouse lens. PLoS One 2012, 6, e28147, doi:10.1371/journal.pone.0028147.
[133]  Son, A.I.; Cooper, M.A.; Sheleg, M.; Sun, Y.; Kleiman, N.J.; Zhou, R. Further analysis of the lens of ephrin-A5(-/-) mice: Development of postnatal defects. Mol. Vis. 2013, 19, 254–266.
[134]  Guo, H.; Miao, H.; Gerber, L.; Singh, J.; Denning, M.F.; Gilliam, A.C.; Wang, B. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res. 2006, 66, 7050–7058, doi:10.1158/0008-5472.CAN-06-0004.
[135]  Mitchell, K.J.; Pinson, K.I.; Kelly, O.G.; Brennan, J.; Zupicich, J.; Scherz, P.; Leighton, P.A.; Goodrich, L.V.; Lu, X.; Avery, B.J.; et al. Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat. Genet. 2001, 28, 241–249, doi:10.1038/90074.
[136]  Naruse-Nakajima, C.; Asano, M.; Iwakura, Y. Involvement of EphA2 in the formation of the tail notochord via interaction with ephrinA1. Mech. Dev. 2001, 102, 95–105, doi:10.1016/S0925-4773(01)00290-8.
[137]  Fang, W.B.; Brantley-Sieders, D.M.; Hwang, Y.; Ham, A.J.; Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 2008, 283, 16017–16026, doi:10.1074/jbc.M709934200.
[138]  Dufour, A.; Egea, J.; Kullander, K.; Klein, R.; Vanderhaeghen, P. Genetic analysis of EphA-dependent signaling mechanisms controlling topographic mapping in vivo. Development 2006, 133, 4415–4420, doi:10.1242/dev.02623.
[139]  Park, E.K.; Warner, N.; Bong, Y.S.; Stapleton, D.; Maeda, R.; Pawson, T.; Daar, I.O. Ectopic EphA4 receptor induces posterior protrusions via FGF signaling in Xenopus embryos. Mol. Biol. Cell 2004, 15, 1647–1655, doi:10.1091/mbc.E03-09-0674.
[140]  Kikawa, K.D.; Vidale, D.R.; van Etten, R.L.; Kinch, M.S. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J. Biol. Chem. 2002, 277, 39274–39279.
[141]  Parri, M.; Buricchi, F.; Taddei, M.L.; Giannoni, E.; Raugei, G.; Ramponi, G.; Chiarugi, P. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J. Biol. Chem. 2005, 280, 34008–34018.
[142]  Saint-Geniez, M.; D’Amore, P.A. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int. J. Dev. Biol. 2004, 48, 1045–1058, doi:10.1387/ijdb.041895ms.
[143]  Gariano, R.F.; Kalina, R.E.; Hendrickson, A.E. Normal and pathological mechanisms in retinal vascular development. Surv. Ophthalmol. 1996, 40, 481–490, doi:10.1016/S0039-6257(96)82014-5.
[144]  Gariano, R.F.; Gardner, T.W. Retinal angiogenesis in development and disease. Nature 2005, 438, 960–966, doi:10.1038/nature04482.
[145]  Stahl, A.; Connor, K.M.; Sapieha, P.; Chen, J.; Dennison, R.J.; Krah, N.M.; Seaward, M.R.; Willett, K.L.; Aderman, C.M.; Guerin, K.I.; et al. The mouse retina as an angiogenesis model. Invest. Ophthalmol. Vis. Sci. 2010, 51, 2813–2826, doi:10.1167/iovs.10-5176.
[146]  Miller, J.W.; Le Couter, J.; Strauss, E.C.; Ferrara, N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology 2013, 120, 106–114, doi:10.1016/j.ophtha.2012.07.038.
[147]  Kempen, J.H.; O’Colmain, B.J.; Leske, M.C.; Haffner, S.M.; Klein, R.; Moss, S.E.; Taylor, H.R.; Hamman, R.F. The prevalence of diabetic retinopathy among adults in the United States. Arch. Ophthalmol. 2004, 122, 552–563.
[148]  Klein, B.E. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007, 14, 179–183, doi:10.1080/09286580701396720.
[149]  Congdon, N.; O’Colmain, B.; Klaver, C.C.; Klein, R.; Munoz, B.; Friedman, D.S.; Kempen, J.; Taylor, H.R.; Mitchell, P. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004, 122, 477–485, doi:10.1001/archopht.122.4.477.
[150]  Friedman, D.S.; O’Colmain, B.J.; Munoz, B.; Tomany, S.C.; McCarty, C.; de Jong, P.T.; Nemesure, B.; Mitchell, P.; Kempen, J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122, 564–572, doi:10.1001/archopht.122.4.564.
[151]  Mechoulam, H.; Pierce, E.A. Retinopathy of prematurity: Molecular pathology and therapeutic strategies. Am. J. Pharmacogenomics 2003, 3, 261–277, doi:10.2165/00129785-200303040-00004.
[152]  Hess, A.R.; Seftor, E.A.; Gardner, L.M.; Carles-Kinch, K.; Schneider, G.B.; Seftor, R.E.; Kinch, M.S.; Hendrix, M.J. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001, 61, 3250–3255.
[153]  Ogawa, K.; Pasqualini, R.; Lindberg, R.A.; Kain, R.; Freeman, A.L.; Pasquale, E.B. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000, 19, 6043–6052, doi:10.1038/sj.onc.1204004.
[154]  Brantley, D.M.; Cheng, N.; Thompson, E.J.; Lin, Q.; Brekken, R.A.; Thorpe, P.E.; Muraoka, R.S.; Cerretti, D.P.; Pozzi, A.; Jackson, D.; et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21, 7011–7026, doi:10.1038/sj.onc.1205679.
[155]  Cheng, N.; Brantley, D.M.; Liu, H.; Lin, Q.; Enriquez, M.; Gale, N.; Yancopoulos, G.; Cerretti, D.P.; Daniel, T.O.; Chen, J. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol. Cancer Res. 2002, 1, 2–11, doi:10.1186/1476-4598-1-2.
[156]  Cheng, N.; Brantley, D.; Fang, W.B.; Liu, H.; Fanslow, W.; Cerretti, D.P.; Bussell, K.N.; Reith, A.; Jackson, D.; Chen, J. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003, 5, 445–456.
[157]  Dobrzanski, P.; Hunter, K.; Jones-Bolin, S.; Chang, H.; Robinson, C.; Pritchard, S.; Zhao, H.; Ruggeri, B. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004, 64, 910–919, doi:10.1158/0008-5472.CAN-3430-2.
[158]  Recchia, F.M.; Xu, L.; Penn, J.S.; Boone, B.; Dexheimer, P.J. Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest. Ophthalmol. Vis. Sci. 2010, 51, 1098–1105, doi:10.1167/iovs.09-4006.
[159]  Chen, J.; Hicks, D.; Brantley-Sieders, D.; Cheng, N.; McCollum, G.W.; Qi-Werdich, X.; Penn, J. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp. Eye Res. 2006, 82, 664–673, doi:10.1016/j.exer.2005.09.004.
[160]  Wang, J.L.; Liu, Y.L.; Li, Y.; Dai, W.B.; Guo, Z.M.; Wang, Z.H.; Zhang, Q. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats. Invest. Ophthalmol. Vis. Sci. 2012, 53, 7348–7357.
[161]  Ojima, T.; Takagi, H.; Suzuma, K.; Oh, H.; Suzuma, I.; Ohashi, H.; Watanabe, D.; Suganami, E.; Murakami, T.; Kurimoto, M.; et al. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am. J. Pathol. 2006, 168, 331–339, doi:10.2353/ajpath.2006.050435.
[162]  Miao, H.; Wang, B. Eph/ephrin signaling in epithelial development and homeostasis. Int. J. Biochem. Cell Biol. 2009, 41, 762–770, doi:10.1016/j.biocel.2008.07.019.
[163]  Costantini, F.; Kopan, R. Patterning a complex organ: Branching morphogenesis and nephron segmentation in kidney development. Dev. Cell 2010, 18, 698–712, doi:10.1016/j.devcel.2010.04.008.
[164]  Wakayama, Y.; Miura, K.; Sabe, H.; Mochizuki, N. EphrinA1-EphA2 signal induces compaction and polarization of Madin-Darby canine kidney cells by inactivating Ezrin through negative regulation of RhoA. J. Biol. Chem. 2011, 286, 44243–44253, doi:10.1074/jbc.M111.267047.
[165]  Kellerman, P.S.; Norenberg, S.L.; Jones, G.M. Early recovery of the actin cytoskeleton during renal ischemic injury in vivo. Am. J. Kidney Dis. 1996, 27, 709–714, doi:10.1016/S0272-6386(96)90107-9.
[166]  Molitoris, B.A. Actin cytoskeleton in ischemic acute renal failure. Kidney Int. 2004, 66, 871–883, doi:10.1111/j.1523-1755.2004.00818.x.
[167]  Molitoris, B.A. Ischemia-induced loss of epithelial polarity: Potential role of the actin cytoskeleton. Am. J. Physiol. 1991, 260, F769–F778.
[168]  Molitoris, B.A.; Dahl, R.; Geerdes, A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am. J. Physiol. 1992, 263, F488–F495.
[169]  Murai, K.K.; Pasquale, E.B. New exchanges in eph-dependent growth cone dynamics. Neuron 2005, 46, 161–163, doi:10.1016/j.neuron.2005.04.004.
[170]  Nahm, O.; Woo, S.K.; Handler, J.S.; Kwon, H.M. Involvement of multiple kinase pathways in stimulation of gene transcription by hypertonicity. Am. J. Physiol. Cell Physiol. 2002, 282, C49–C58, doi:10.1152/ajpcell.00267.2001.
[171]  Ivanov, A.I.; Steiner, A.A.; Scheck, A.C.; Romanovsky, A.A. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats. Physiol. Genomics 2005, 21, 152–160, doi:10.1152/physiolgenomics.00043.2004.
[172]  Li, Z.; Tanaka, M.; Kataoka, H.; Nakamura, R.; Sanjar, R.; Shinmura, K.; Sugimura, H. EphA2 up-regulation induced by deoxycholic acid in human colon carcinoma cells, an involvement of extracellular signal-regulated kinase and p53-independence. J. Cancer Res. Clin. Oncol. 2003, 129, 703–708, doi:10.1007/s00432-003-0493-z.
[173]  Matsuo, K.; Irie, N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 2008, 473, 201–209, doi:10.1016/j.abb.2008.03.027.
[174]  Matsuo, K.; Ray, N. Osteoclasts, mononuclear phagocytes, and c-Fos: New insight into osteoimmunology. Keio J. Med. 2004, 53, 78–84, doi:10.2302/kjm.53.78.
[175]  Lacey, D.L.; Timms, E.; Tan, H.L.; Kelley, M.J.; Dunstan, C.R.; Burgess, T.; Elliott, R.; Colombero, A.; Elliott, G.; Scully, S.; et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93, 165–176, doi:10.1016/S0092-8674(00)81569-X.
[176]  Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 1998, 95, 3597–3602, doi:10.1073/pnas.95.7.3597.
[177]  Hennighausen, L.; Robinson, G.W. Information networks in the mammary gland. Nat. Rev. Mol. Cell. Biol. 2005, 6, 715–725, doi:10.1038/nrm1714.
[178]  Watson, C.J.; Khaled, W.T. Mammary development in the embryo and adult: A journey of morphogenesis and commitment. Development 2008, 135, 995–1003, doi:10.1242/dev.005439.
[179]  Andres, A.-C.; Ziemiecki, A. Eph and ephrin signaling in mammary gland morphogenesis and cancer. J. Mammary Gland Biol. Neoplasia 2003, 8, 475–485, doi:10.1023/B:JOMG.0000017433.83226.22.
[180]  Munarini, N.; Jager, R.; Abderhalden, S.; Zuercher, G.; Rohrbach, V.; Loercher, S.; Pfanner-Meyer, B.; Andres, A.C.; Ziemiecki, A. Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase. J. Cell. Sci. 2002, 115, 25–37.
[181]  Haldimann, M.; Custer, D.; Munarini, N.; Stirnimann, C.; Zurcher, G.; Rohrbach, V.; Djonov, V.; Ziemiecki, A.; Andres, A.C. Deregulated ephrin-B2 expression in the mammary gland interferes with the development of both the glandular epithelium and vasculature and promotes metastasis formation. Int. J. Oncol. 2009, 35, 525–536.
[182]  Sternlicht, M.D.; Kouros-Mehr, H.; Lu, P.; Werb, Z. Hormonal and local control of mammary branching morphogenesis. Differentiation 2006, 74, 365–381, doi:10.1111/j.1432-0436.2006.00105.x.
[183]  Nikolova, Z.; Djonov, V.; Zuercher, G.; Andres, A.C.; Ziemiecki, A. Cell-type specific and estrogen dependent expression of the receptor tyrosine kinase EphB4 and its ligand ephrin-B2 during mammary gland morphogenesis. J. Cell. Sci. 1998, 111, 2741–2751.
[184]  Zelinski, D.P.; Zantek, N.D.; Walker-Daniels, J.; Peters, M.A.; Taparowsky, E.J.; Kinch, M.S. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase. J. Cell. Biochem. 2002, 85, 714–720, doi:10.1002/jcb.10186.
[185]  Martin, K.J.; Patrick, D.R.; Bissell, M.J.; Fournier, M.V. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 2008, 3, e2994, doi:10.1371/journal.pone.0002994.
[186]  Fournier, M.V.; Martin, K.J.; Kenny, P.A.; Xhaja, K.; Bosch, I.; Yaswen, P.; Bissell, M.J. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 2006, 66, 7095–7102, doi:10.1158/0008-5472.CAN-06-0515.
[187]  Ireton, R.C.; Chen, J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr. Cancer Drug Targets 2005, 5, 149–157, doi:10.2174/1568009053765780.
[188]  Kamat, A.A.; Coffey, D.; Merritt, W.M.; Nugent, E.; Urbauer, D.; Lin, Y.G.; Edwards, C.; Broaddus, R.; Coleman, R.L.; Sood, A.K. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 2009, 115, 2684–2692, doi:10.1002/cncr.24335.
[189]  Pollard, J.W. Tumour-stromal interactions. Transforming growth factor-beta isoforms and hepatocyte growth factor/scatter factor in mammary gland ductal morphogenesis. Breast Cancer Res. 2001, 3, 230–237, doi:10.1186/bcr301.
[190]  Bianchi, L.M.; Liu, H. Comparison of ephrin-A ligand and EphA receptor distribution in the developing inner ear. Anat. Rec. 1999, 254, 127–134, doi:10.1002/(SICI)1097-0185(19990101)254:1<127::AID-AR16>3.0.CO;2-Q.
[191]  Pickles, J.O.; Claxton, C.; van Heumen, W.R. Complementary and layered expression of Ephs and ephrins in developing mouse inner ear. J. Comp. Neurol. 2002, 449, 207–216, doi:10.1002/cne.10231.
[192]  Van Heumen, W.R.; Claxton, C.; Pickles, J.O. Expression of EphA4 in developing inner ears of the mouse and guinea pig. Hear. Res. 2000, 139, 42–50, doi:10.1016/S0378-5955(99)00158-6.
[193]  Howard, M.A.; Rodenas-Ruano, A.; Henkemeyer, M.; Martin, G.K.; Lonsbury-Martin, B.L.; Liebl, D.J. Eph receptor deficiencies lead to altered cochlear function. Hear. Res. 2003, 178, 118–130, doi:10.1016/S0378-5955(03)00068-6.
[194]  Torres, M.; Giraldez, F. The development of the vertebrate inner ear. Mech. Dev. 1998, 71, 5–21, doi:10.1016/S0925-4773(97)00155-X.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133